or Try an Advanced Search...

    Technical Analysis for DRMA - Dermata Therapeutics, Inc.

    Grade Last Price % Change Price Change
    F 0.33 -1.33% 0.00
    DRMA closed down 1.33 percent on Wednesday, May 8, 2024, on 50 percent of normal volume.
    Earnings due: May 16
    *** please verify all earnings dates ***
    1 Watcher
    Watchlist Portfolio

    Trend Table & Recent EOD Trading Signals

    ADX Long Term Intermediate Term Short Term
    Weak or Absent Down Down Down
    Historical DRMA trend table...
    Date Alert Name Type % Chg
    20 DMA Resistance Bearish 0.00%
    Wide Bands Range Expansion 0.00%
    20 DMA Resistance Bearish -1.33%
    Wide Bands Range Expansion -1.33%
    20 DMA Resistance Bearish -4.11%
    Shooting Star Candlestick Bearish -4.11%
    Non-ADX 1,2,3,4 Bearish Bearish Swing Setup -4.11%
    Wide Bands Range Expansion -4.11%
    20 DMA Resistance Bearish -2.80%
    Shooting Star Candlestick Bearish -2.80%
    Older End-of-Day Signals for DRMA ...

       Recent Intraday Alerts

    Alert Time
    Down 5% about 14 hours ago
    60 Minute Opening Range Breakdown about 15 hours ago
    Down 3% about 15 hours ago
    Fell Below Previous Day's Low about 15 hours ago
    Down 2 % about 15 hours ago
    View Earlier Intraday Alerts

    Get a Trading Assistant

    Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
    Analyze My Stocks!
    Configure default chart indicators
    DRMA Chart by TradingView
    Basic chart:

    Profile

    Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the treatment of medical and aesthetic skin conditions. Its lead product candidate is DMT310, a once-weekly topical product that is under clinical development for the treatment of acne vulgaris, psoriasis vulgaris, and papulopustular rosacea. The company was founded in 2014 and is headquartered in San Diego, California.
    Classification
    Sector: Healthcare
    Industry: Biotechnology
    Keywords: Biotechnology Organ Systems Dermatology Psoriasis Acne Rosacea Skin Acne Vulgaris Cutaneous Conditions

    Is DRMA a Buy, Sell or Hold?

    Indicator Bull Case Neutral / Hold Bear Case
    50 DMA
    200 DMA
    ADX Trend
    Oversold / Overbought
    Relative Strength
    Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.

    Recent News

    Date Title
    Apr 2 Presenting on the Emerging Growth Conference 69 Day 1 on April 3 Register Now
    Mar 27 Dermata to Present at the Emerging Growth Conference on April 3, 2024
    Mar 21 Dermata Therapeutics GAAP EPS of -$2.67 beats by $1.55
    Mar 21 Dermata Therapeutics Provides Corporate Update and Reports Full Year 2023 Financial Results
    Feb 6 Presenting on the Emerging Growth Conference 67 Day 1 on February 7 Register Now
    Feb 1 Dermata to Present at the Emerging Growth Conference on February 7, 2024
    Jan 5 Dermata stock soars on patent issuance, partnership talks
    Jan 4 Dermata Expands Global Intellectual Patent Portfolio with Issuance of Japanese Patent for DMT410 for the Treatment of Hyperhidrosis
    Dec 20 Dermata Enrolls First Patient in Pivotal DMT310 Phase 3 STAR-1 Clinical Trial for Acne
    Dec 8 Dermata Therapeutics files for resale of up to 7.2M shares
    See more DRMA news...

    Comments

    View full discussion...

    Indicators

    Indicator Value
    52 Week High 3.68
    52 Week Low 0.232
    Average Volume 116,521
    200-Day Moving Average 0.70
    50-Day Moving Average 0.38
    20-Day Moving Average 0.34
    10-Day Moving Average 0.34
    Average True Range 0.03
    RSI (14) 41.52
    ADX 17.15
    +DI 15.39
    -DI 22.62
    Chandelier Exit (Long, 3 ATRs) 0.34
    Chandelier Exit (Short, 3 ATRs) 0.32
    Upper Bollinger Bands 0.40
    Lower Bollinger Band 0.28
    Percent B (%b) 0.42
    BandWidth 36.44
    MACD Line -0.02
    MACD Signal Line -0.02
    MACD Histogram 0.0022
    Fundamentals Value
    Market Cap 1.16 Million
    Num Shares 3.54 Million
    EPS -4.42
    Price-to-Earnings (P/E) Ratio -0.07
    Price-to-Sales 0.00
    Price-to-Book 0.24
    Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
    Resistance 4 (R4) 0.37
    Resistance 3 (R3) 0.37 0.36 0.36
    Resistance 2 (R2) 0.36 0.35 0.36 0.36
    Resistance 1 (R1) 0.34 0.34 0.33 0.34 0.36
    Pivot Point 0.33 0.33 0.32 0.33 0.33
    Support 1 (S1) 0.31 0.32 0.30 0.31 0.29
    Support 2 (S2) 0.30 0.31 0.30 0.29
    Support 3 (S3) 0.28 0.30 0.29
    Support 4 (S4) 0.28